AI Image
Gilead's IBS drug succeeds in mid-stage trial
STAT • • business
Key Points:
- Gilead Sciences reported mid-stage study results showing that its oral treatment, emvistegrast, eliminated symptoms in patients with moderate to severe ulcerative colitis, an inflammatory bowel disease.
- A 200-milligram daily dose of emvistegrast for 12 weeks achieved a 23% placebo-adjusted clinical remission rate, surpassing Wall Street analyst expectations.
- The Phase 2 study's statistically significant improvement suggests emvistegrast could become a best-in-class oral therapy for ulcerative colitis patients.
- Gilead’s senior VP highlighted that many patients with inflammatory bowel disease do not achieve remission with current therapies, making these results particularly encouraging.
